Furthermore, although MTA levels are elevated in MTAP-deleted cancers, the different levels of SAM, MTA, and other metabolic intermediates may vary across cells and tissues so that PRMT5 vulnerability may be impacted non-uniformly even in genetically defined backgrounds. This evidence concerns the gene PRMT5 and cancer.